Edgewise Therapeutics to Present at Upcoming Investor Conferences

BOULDER, Colo.--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, announced today that members of its senior management team will participate in the following upcoming investor conferences:

Stifel 2023 Healthcare Conference
Presentation: Wednesday, November 15, 2023, at 10:55 am ET

Piper Sandler 35th Annual Healthcare Conference
Presentation: Wednesday, November 29, 2023, at 8:00 am ET

The presentations will be webcast live; links for the webcasts can be found on the Edgewise events page and will be accessible for replay following the presentations. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.

About Edgewise Therapeutics

Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company’s deep expertise in muscle physiology is driving a new generation of first-in-class therapeutics. EDG-5506 is an orally administered skeletal myosin inhibitor in clinical trials in patients with Becker, Duchenne, and Limb-Girdle muscular dystrophies as well as McArdle Disease. EDG-7500, currently in a Phase 1 trial, is a novel cardiac sarcomere modulator for the treatment of HCM and other disorders of cardiac diastolic dysfunction. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X (formerly Twitter), Facebook, Instagram and Threads.

This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231108004645/en/

Investors & Media
Michael Carruthers
Chief Financial Officer
[email protected]

Source: Edgewise Therapeutics

You May Also Be Interested In

• ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
• Quadient Digital Delivers Over 20% Q2 Bookings Growth, Driven by AI-Powered Automation and E-Invoicing
• American Chemical Society Names Syngenta's Camilla Corsi the 2026 Winner of Prestigious International Award for Research in Agrochemicals